Drug profile

The FDA adverse-event record for Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn

448 FDA reports name Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#329 of 2,679
by report volume (all drugs)
448
adverse-event reports
85.0%
death-coded share
Cattle
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn ranks #328 of 2679 by total reports (448) and #16 of 1130 by death-coded share (85.0%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#328
This drug, reports of 2679
#16
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn has 448 reports now versus 448 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn changes

Signature read: Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn's 85.0% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
448
Total Reports
381
Deaths Reported
85.0%
Death-coded share of reports

Active Ingredients

Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn

Administration Routes

UnknownNasalSubcutaneousIntramuscularOral

Species Affected

Cattle 445
Unknown 3

Most Affected Breeds

Cattle (other) 226
Mixed (Cattle) 115
Holstein-Friesian also known as Holstein 54
Crossbred Bovine/Cattle 17
Aberdeen Angus 16
Cattle (unknown) 6
Unknown 3
Jersey 3
Hereford cattle 2
Brangus 2

Most Reported Reactions

Lack of efficacy (bacteria) - NOS 267
Death 243
Lack of efficacy - NOS 130
Abnormal test result 51
Unrelated death 46
CULTURE/TITER DATA ABNORMAL 40
Abnormal necropsy finding 34
Increased mortality rate 32
Other abnormal test result NOS 28
NT - Abnormal necropsy finding NOS 23
Death by euthanasia 20
PR-LUNG(S), LESION(S) 16

Outcome Breakdown

Died
373 (48.4%)
Outcome Unknown
278 (36.1%)
Recovered/Normal
48 (6.2%)
Ongoing
45 (5.8%)
Euthanized
15 (1.9%)
Recovered with Sequela
11 (1.4%)

Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

  • Compare Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6), Mlv; Bovine Respiratory Syn (#329 of 2,679 by report volume); death-coded 85.0%. PlainBreed drug row · death-coded share stamp 85.0% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →